FOLH1 and posterior cortical atrophy: Both for PCa diagnostics and treatment monitoring, positron emission tomography (PET) has proven to be an immensely valuable clinical imaging modality, particularly with the introduction of, first, 68Ga-, and soon after, 18F-labelled tracers incorporating the prostate-specific membrane antigen (PSMA) (Mease et al. 2013).